Pembrolizumab Clinical Trials

A listing of Pembrolizumab medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy

The purpose of this study is to test any good and bad effects of the combination of study drugs called MK-3475 (pembrolizumab) and talimogene laherparepvec (T-VEC) in melanoma patients.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma

This study is for women with advanced or recurrent endometrial cancer using Pembrolizumab in combination with Carboplatin and Paclitaxel chemotherapy.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Phase II Study of Pembrolizumab an anti-PD (programmed cell death)-1 Antibody in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

This study is being done to see what effects the combination of pembrolizumab and carboplatin have on breast cancer compared to carboplatin alone.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with merkel cell cancer that has spread to other places in the body.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ? 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor

This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit with a PD-1 or PD-L1 inhibitor.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475), to look for the highest dose of pembrolizumab that can be given safely without serious side effects, to find out how pembrolizumab is absorbed and broken down, and to …

  • 0 views
  • 19 Feb, 2024
  • 1 location